HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA

HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA

Abstract Background Certain risk alleles associated with autoantibody-positive rheumatoid arthritis (RA) have been linked to poorer prognoses. In patients with autoantibody-positive RA, abatacept shows differential efficacy to tumor necrosis factor inhibitors. Our aim was to investigate the relation...

Full description

Bibliographic Details
Main Authors: William Rigby, Jane H. Buckner, S. Louis Bridges, Marleen Nys, Sheng Gao, Martin Polinsky, Neelanjana Ray, Vivian Bykerk
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Arthritis Research & Therapy
Subjects:
Abatacept
Adalimumab
Anti-citrullinated protein antibodies
Biological therapy
Arthritis, rheumatoid
Therapeutics
Online Access:https://doi.org/10.1186/s13075-021-02607-7

Internet

https://doi.org/10.1186/s13075-021-02607-7

Similar Items